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Abstract
Background: Modern radiotherapy (RT) reduces the side effects at organ at risk. However, skin
toxicity is still a major problem in many entities, especially head and neck cancer. Some substances
like chemotherapy provide a risk of increased side effects or can induce a "recall phenomenon"
imitating acute RT-reactions months after RT. Moreover, some phototoxic drugs seem to enhance
side effects of radiotherapy while others do not. We report a case of "radiation recall dermatitis"
(RRD) one year after RT as a result of taking hypericin (St. John's wort).
Case report: A 65 year old man with completely resected squamous cell carcinoma of the
epiglottis received an adjuvant locoregional RT up to a dose of 64.8 Gy. The patient took hypericin
during and months after RT without informing the physician. During radiotherapy the patient
developed unusual intensive skin reactions. Five months after RT the skin was completely bland at
the first follow up. However, half a year later the patient presented erythema, but only within the
area of previously irradiated skin. After local application of a steroid cream the symptoms
diminished but returned after the end of steroid therapy. The anamnesis disclosed that the patient
took hypericin because of depressive mood. We recommended to discontinue hypericin and the
symptoms disappeared afterward.
Conclusion: Several drugs are able to enhance skin toxicity of RT. Furthermore, the effect of RRD
is well known especially for chemotherapy agents such as taxans. However, the underlying
mechanisms are not known in detail so far. Moreover, it is unknown whether photosensitising
drugs can also be considered to increase radiation sensitivity and whether a recall phenomenon is
possible. The first report of a hypericin induced RRD and review of the literature are presented.
In clinical practise many interactions between drugs and radiotherapy were not noticed and if
registered not published. We recommend to ask especially for complementary or alternative drugs
because patients tend to conceal such medication as harmless.
Findings
Although the introduction of higher voltage radiotherapy
reduced severe cutaneous side effects in the past, today
particularly chemotherapy can sensitise skin to radiation
resulting an acute skin reactions of higher degree [1-4].
The cutaneous side effect ranges from erythema up to
moist epitheliolysis. The wound healing of radiation
induced acute side effects is normally finished after some
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weeks or months after RT and corresponding to the acute
skin reaction. This phenomenon is called radiation recall
dermatitis (RRD) and may be induced by drugs, however,
disappears after removing the inducing substance again.
RRD is described for several chemotherapy agents [5]. So
far, both a sensitising effect and RRD of drugs apart from
chemotherapy are not systematically analysed.
We report on a patient having developed RRD one year
after radiotherapy induced by a hypericin (St. John's
wort). Additionally a literature overview on photo- and
radiation sensitising substances is presented.
Case report
A 65-year old patient with a squamous cell carcinoma of
the epiglottis diagnosed 11/2003 received a laser-surgi-
cally organ preserving operation. From February to April
2004 a postoperative radiotherapy was done encompass-
ing the region of the primary cancer including the cervical
and supraclavicular lymphatic regions. Total dose was
64,8 Gy, single dose 1,8 Gy. A multiple-field technique
was used by combination of photons and electrons. Dur-
ing the forth week the patient developed a distinctive ery-
thema (WHO II), which changed to moist epitheliolysis
(WHO III) at fifth week. At the end of radiotherapy moist
epitheliolysis with crust occurred (Figure 1). Five months
after radiotherapy the skin was completely recovered, only
hyper- and hypopigmentation were visibly. At the regular
following date one year after radiotherapy the patient
showed a renewed distinctive erythema exclusively within
the former irradiated skin region (Figure 2). The erythema
rised after sunbathe and resembled the clinical picture of
a radiogenic acute-reaction. According to prescription of a
cream containing steroids skin-efflorescences recovered,
but appeared again unchangedly after going of the cream
for a short time. On a specific questioning the patient
reported for the first time to take hypericin (Johanniskraut
Sandos 425) within the last few years. After stopping tak-
ing the medicine the erythema faded away completely in
short time (Figure 3).
Discussion
Different medicinal drugs can sensitise the skin to UV
radiation or visible light (photosensitivity), x-rays (radia-
tion sensitivity) or can induce a radiation recall dermatitis
(RRD) (Tab. 1) [6]
Photosensitivity occurs both as a phototoxic, non-immu-
nologic phenomenon and as a photoallergic, immune-
dependent reaction. The much more common phototox-
icity can be subdivided into a photodynamic type, which
requires oxygen, and a nonphotodynamic, which does
not [7]. The majority of photosensitising drugs have an
action spectrum within UVA. The photosensitising effect
of several substances, e.g. Hypericin, is used for photody-
namic therapy against cancer [8,9].
Especially chemotherapeutic agents can increase the radi-
ation sensitivity of the skin. These substances may lead
not only to enhanced acute cutaneous side effects, but
induce skin efflorescences for months afterwards, which
resemble closely the acute skin reaction to radiotherapy.
This delayed reaction is called radiation recall dermatitis
(RRD), an inflammatory skin reaction after administra-
tion of certain promoting agents, such as antineoplastic
drugs, in a previously irradiated area. First reports on RRD
date back to 60 years. So far there is no systematic over-
view on incidence and aetiology of RRD but only case
reports. In these reports RRD was described as varying
from moderately rare to moderately common side effect
caused by unknown mechanisms [10]. However, some
drugs, especially chemotherapy agents, seem to induce
RRD more frequently. Camidge described an increased
RRD risk for several chemotherapies, for examples Actin-
omycin D, Adriamycin or Paclitaxel [10]. Additionally,
reports on Tamoxifen and tuberculostatic therapy are
found in literature.
The time between the end of radiation and RRD varies
extremely. A median of 39 days with a range between 7
Skin toxicity at the end of radiotherapy (RT)Figure 1
Skin toxicity at the end of radiotherapy (RT). During the 
forth weeks of the RT the described patient developed a dis-
tinctive erythema (WHO II), which changed to moist epithe-
liolysis (WHO III) at the fifth week. At the end of the 
radiotherapy moist epitheliolysis with crust occurred. As 
well, the skin remained hyper-pigmented.Page 2 of 5
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and the first appearance of skin reaction depends on the
administration. While first skin reaction is described
immediately after an intravenous application, it takes
some days after oral application. So far, there are no rec-
ommendations on a standard therapy of the RRD. On
contrary the treatment of the RRD is discussed controver-
sially in literature. Some authors recommend the systemic
or local application of steroids or antihistaminics, others
refuse [11,12]. The application of steroids may reduce
skin reaction, but stopping the therapy may result in a
rebound phenomenon as shown in our patient. As such,
the role for systemic steroids, topical steroids or anti-his-
tamines in the treatment of acute RRD remains unclear.
There is consent that the RRD triggering substance should
be removed immediately [10]. In our case report the dis-
continuation of the drug led to a complete healing of the
skin efflorescences in a short time.
The aetiology of the RRD is still unclear. A lot of different
hypotheses have been discussed for RRD although there is
a little evidence basing to support any of them. The
hypotheses include vascular damage, epithelial stem cells
inadequacy, epithelial stem cell sensitivity or drug hyper-
sensitivity reactions. Even skin biopsies showing non-spe-
cific changes couldn't clear the aetiology of the RRD [11].
Reports on an increased radiation sensitivity induced by
non-chemotherapeutic substances are rare in literature.
However, there are a lot of drugs with a described photo-
sensitising effect. Photosensitising as a typical side effect is
indicated for 76 drugs approved in Germany and listed in
" Rote Liste" [13].
Phytotherapy can also induce photosensitising. Phytop-
harmaca are drugs which contain exclusively plants,
plant-parts or plant-components or combinations of it in
finished or untreated condition as active components and
belong to comparative or alternative medicine. Comple-
mentary and alternative medicine is more common
among patients with cancer than in the general popula-
tion [14]. In the 1990s metaanalyses of 26 studies con-
ducted worldwide showed that phytopharmaca were
widely used by cancer patients with a prevalence ranging
from 75 to 64% [15]. In 2002 a more recent study
reported on an increase of this use up to 83% [16]. There-
fore the market for alternative drugs has a volume of over
4 billion dollars in the USA and 6.7 billion dollars in
Skin efflorescence after leaving out StFigure 3
Skin efflorescence after leaving out St. John's wort. Despite 
the prescription of a steroid containing cream the skin efflo-
rescences recovered, but appeared again unchanged after 
leaving out the cream for a short time. On a specific ques-
tioning the patient reported for the first time to take hyper-
icin (Johanniskraut Sandos 425) within the last few years. 
After stopping taking the medicine the erythema faded away 
completely in short time.
Skin efflorescence after sunbathe one year after RT-endFigure 2
Skin efflorescence after sunbathe one year after RT-end. 
About a half year after RT in the aftercare the skin was com-
pletely recovered, only hyper- and hypopigmentation were 
visibly. At the regular following date one year after radiother-
apy the patient showed a renewed distinctive erythema 
exclusively within the former irradiated skin region. The ery-
thema appeared after sunbathe and resembled the clinical 
picture of the previous radiogenic acute-reaction.Page 3 of 5
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939 million euros [18].
In the USA up to 72% of the patients with cancer using
alternative medicine do not inform their treating physi-
cian [19,20]. An estimated 15 million adults combine
alternative remedies with prescription medicine [21].
In a recent study Rieger et al. reported that at least 20 % of
the hospitalises patients take additional substances with-
out informing the attending physicians. He reported that
urine samples of 20% of patients were positive tested for
a compound of unknown co-medication [22]. Martin-
Facklam et al. evaluated the extent of systemic exposure to
St. John's wort in patients on admission and during hos-
pital stay, and compared the results with known use of St.
John's wort as documented in the drug chart and detected
in additional interviews. Hyperforin or hypericin were
detected in 11.3 % of patients. Six percent of patients had
taken St. John's wort without the knowledge of the medi-
cal team and the pharmacist, in spite of additional inter-
views and seven of these patients were treated
concurrently with drugs that can interact with St. John's
wort [23]. In the USA more than 100000 deaths per year
can be attributed to drug interaction and it has been sug-
gested that the greater part of these might be linked to the
use of herbs [24,25].
St. John's wort is one of the most extensively studied
Hypericum. Today St. John's wort is widely used for the
treatment of mild to moderate depression and other nerv-
ous conditions [15,26]. It is a complex mixture of more
than two dozen compounds influencing drug-metabolis-
ing enzymes, drug transporters and pharmacokinetic [27],
e.g. relevant for patients using Digoxin [28], Theophyllin
[29], Cyclosporine [30], oral Contraceptive [31], Phen-
procoumon [32], Warfarin [33] and Sertaline [34]. Addi-
tionally a photo sensitising effect of St. John's wort is well
described in the literature of human as well as veterinary
medicine [8,9,35-37]. Beattie et al. describe decreased ery-
themal threshold to ultraviolet A1 irradiation as mecha-
nism for the photo sensitising effect of St John's wort [38].
Zhang et al. even reported on an enhancement of radia-
tion sensitivity by Hypericin in glioma cells [39].
In patients, who self-prescribe herbal medicinal products,
the risk of increased cutaneous side effects by radiother-
apy like the reported RRD is enhanced. So fare the mech-
anism responsible for the increased radiation sensitivity is
unclear. As described above, herbal medicines are used by
a major part of patients with cancer, which are irradiated
frequently in combination with chemotherapy.
Retrospectively it may be suggested that the acute side
effects during radiotherapy were enhanced by the addi-
tional use of St. John's wort in our reported case. But it
may safely assert that the RRD one year after radiotherapy
was induced by St. John's wort, because RRD healed up by
discontinuity of its use.
Phytopharmaca are frequently used by a major part of
patients with cancer. Therefore the radiation oncologist
regularly sees patients who self-describe herbal medicinal
products but do not volunteer this information. This co-
medication can increase the toxicity of anticancer therapy.
In the reported case the acute and the late cutaneous tox-
icity was increased probably by a radiation sensitising
effect of St. John's wort. As a consequence of this all
patients should be questioned about co-medicine, espe-
cially complementary and alternative medicine like phy-
topharmaca.
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